Healios
Our mission is to foster a “Life Explosion” that enriches the lives of people around the world.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| JPY | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 52 % | 120 % | 34 % | 363 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (14693 %) | (8288 %) | (4938 %) | (2230 %) | (388 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (20415 %) | (11976 %) | (5743 %) | (3160 %) | (756 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 11059 % | 9024 % | 4231 % | 1904 % | 350 % |
Source: Company filings or news article
Related Content
Healios K.K. is a pioneering biotechnology company specializing in regenerative medicine, focusing on the development and commercialization of treatments using induced pluripotent stem cells (iPSCs). The company serves a global market, targeting serious conditions such as ischemic stroke and age-related macular degeneration. Healios operates through strategic partnerships and licensing agreements with leading institutions like Nikon Corporation, Athersys, Inc., and RIKEN. The business model revolves around research and development, followed by licensing and commercialization of its proprietary cell therapy products. Revenue is generated through product sales, licensing fees, and milestone payments. Healios aims to bring cutting-edge medical solutions to market efficiently, leveraging its robust intellectual property portfolio and strategic alliances.
Keywords: regenerative medicine, iPSC technology, cell therapy, ischemic stroke, macular degeneration, biotechnology, licensing agreements, strategic partnerships, commercialization, intellectual property.
Tech stack
Investments by Healios
Edit